Menu Share scam alert In recent years, many companies have become aware that their shareholders have received unsolicited phone calls or correspondence concerning investment matters. These are typically from overseas-based ‘brokers’, working for firms that have become known as ‘boiler rooms’, who target shareholders, offering to sell them what often turn out to be worthless or high risk shares, or by offering investment opportunities to purchase newly-issued guaranteed income bonds. These ‘brokers’ can be very persistent and extremely persuasive. It is not just novice investors who have been duped in this way. Many victims have been successfully investing for several years. Shareholders are advised to be very wary of any unsolicited advice, offers to buy shares at a discount or bonds with a guaranteed income, or offers of free company reports. If you receive any unsolicited investment advice, we recommend that you: make sure you get the name of the person and organisation check that the firm is properly authorised before getting involved by visiting the FCA register of authorised firms do not give out any personal information until you are certain the scheme is legitimate if you have any concerns, report the matter to the FCA either by calling 0800 111 6768 or by using this online form. The FCA publishes a list of these unauthorised firms on its website. If one of these firms contacts you by phone, the best course of action is to hang up. If you deal with an unauthorised firm, you will not be eligible to receive payment under the Financial Services Compensation Scheme or have access to the Financial Ombudsman Service. If you have already paid money to share fraudsters you should contact Action Fraud on 0300 123 2040. GSK is aware that shareholders have received, and continue to receive, unsolicited communications from various third parties prompting shareholders to buy or sell their GSK securities, or inviting them to invest in bond issuances. We strongly recommend that all calls and emails received from third parties persuading shareholders to deal in GSK securities or partake in bond investing be ignored as they may be scams. We encourage all shareholders to be cautious and report any suspicious activity to the FCA using the contact details provided above. You should never give out your personal details or click on a link in an unsolicited email as it could compromise your personal or internet security. If in doubt, please contact GSK directly. Details of any share dealing facilities that GSK endorses will be included in company mailings. For more information on investment scams, please visit the FCA website. RSS Other GSK websites Market website selector GSKPro for healthcare professionals GSK Study Register Quick links COVID-19 response Behind the science About us Products Careers Investors Media Research and development Responsibility Accessibility/legal Accessibility Terms of use Cookie policy Privacy notice Modern Slavery Act statement 2020 PDF - 191.4KB Sitemap Contact us Contact us Partnerships Report a possible side effect Business to business Supplier website Business to business This is our global website, intended for visitors seeking information on GSK’s worldwide business. Our market sites can be reached by visiting our market selector. © 2001-2021 GlaxoSmithKline plc. All rights reserved. Trade marks are owned by or licensed to the GSK group of companies. GlaxoSmithKline plc. Registered in England and Wales No. 3888792. Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom. We use cookies GSK values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Others are optional: performance cookies show us how you use our website and features; functional cookies remember your preferences; and advertising cookies help us share relevant content.Cookie Policy Show detail ❮ OPT OUT ACCEPT ALL